| Serial Number | 98880595 |
| Word Mark | REXHYLA |
| Filing Date | Monday, December 2, 2024 |
| Status | 686 - PUBLISHED FOR OPPOSITION |
| Status Date | Tuesday, January 13, 2026 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, January 13, 2026 |
| Goods and Services | Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressant preparations, pharmaceutical antibodies for medical use, and immunotherapy preparations for the treatment of cancer; cytokine inhibitory drugs for human use being pharmaceutical preparations for the treatment of cancer; pharmaceutical anticoagulants for human use; Pharmaceutical preparations for human use that modulate the immune system for the treatment of immune-system related diseases and disorders; Pharmaceutical and biological preparations for human use for immunotherapy, namely T Cell therapy preparations for the treatment of cancer; Pharmaceutical and biological preparations for human use, namely, stem cells for medical use; Pharmaceutical preparations for human use for the treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, antivirals for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, monoclonal antibodies for medical use; Pharmaceutical preparations for human use for the treatment of neuropsychiatric disorders; therapeutic radiopharmaceutical preparations for human use for the treatment of cancer and solid tumors; diagnostic radiopharmaceutical preparations for human use; diagnostic pharmaceutical preparations for human use for medical purposes; radiopharmaceutical preparations for human use in the nature of imaging and detection agents for diagnosing and monitoring cancer; biological preparations for human use in the nature of radio-isotope markers for therapeutic or diagnostic use; Pharmaceutical preparations for human use for the treatment of cystic fibrosis; Pharmaceutical preparations for human use for the treatment and prevention of respiratory diseases. |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Monday, December 2, 2024 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | Bristol-Myers Squibb Company |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 03 - Corporation |
| Address | Princeton, NJ 08543 |
| Party Name | Bristol-Myers Squibb Company |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | Princeton, NJ 08543 |
| Event Date | Event Description |
| Monday, December 2, 2024 | NEW APPLICATION ENTERED |
| Wednesday, June 4, 2025 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Thursday, June 5, 2025 | ASSIGNED TO EXAMINER |
| Thursday, June 5, 2025 | NON-FINAL ACTION WRITTEN |
| Thursday, June 5, 2025 | NON-FINAL ACTION E-MAILED |
| Thursday, June 5, 2025 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Wednesday, September 3, 2025 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Wednesday, September 3, 2025 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Thursday, September 4, 2025 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Friday, September 19, 2025 | FINAL REFUSAL WRITTEN |
| Friday, September 19, 2025 | FINAL REFUSAL E-MAILED |
| Friday, September 19, 2025 | NOTIFICATION OF FINAL REFUSAL EMAILED |
| Thursday, December 11, 2025 | TEAS REQUEST FOR RECONSIDERATION RECEIVED |
| Thursday, December 11, 2025 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Thursday, December 11, 2025 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Wednesday, December 17, 2025 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Wednesday, January 7, 2026 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Tuesday, January 13, 2026 | PUBLISHED FOR OPPOSITION |
| Tuesday, January 13, 2026 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |